WeVote
Log In

Bill

Bill

HB 2549

Mandating insurance coverage of pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS).

2025-2026 Regular Session

Kansas bill mandates insurance coverage for PANS/PANDAS diagnosis and treatment, expanding pediatric neuropsychiatric care access despite ongoing medical-community diagnostic debate.

Died in Committee
#insurance
0
WeVote Research Nonpartisan
Bill Summary · HB 2549

Legislative bill overview

HB 2549 would require health insurance plans in Kansas to cover diagnostic testing and treatment for PANS (pediatric acute-onset neuropsychiatric syndrome) and PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections). The bill mandates insurance coverage for conditions that some view as distinct medical diagnoses but that remain scientifically controversial in the broader medical community.

Why is this important

This bill directly affects what treatments insurance must cover for children experiencing sudden-onset psychiatric symptoms, potentially expanding access to care for families whose children develop these conditions. The outcome will influence healthcare costs, insurance premiums, and treatment options available to Kansas families, while also setting a precedent for how the state approaches coverage of contested diagnoses.

Potential points of contention

  • Scientific consensus uncertainty: While PANS/PANDAS have advocates in the medical community, major medical organizations (including the American Psychiatric Association and many pediatric immunologists) have not established these as definitively distinct diagnostic entities, raising questions about mandating coverage for conditions lacking broad clinical consensus.
  • Cost implications: Mandatory coverage expansions typically increase insurance costs, which may be passed to consumers through higher premiums, deductibles, or employer contributions, affecting the broader insurance market.
  • Treatment standardization concerns: Coverage mandates may drive prescribing patterns toward specific treatments (such as antibiotics or immunological interventions) before robust clinical guidelines exist, potentially leading to unnecessary or ineffective treatments.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.